Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates
- 29 February 2004
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 48 (2) , 137-143
- https://doi.org/10.1016/j.diagmicrobio.2003.09.004
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Linezolid Resistance since 2001: SENTRY Antimicrobial Surveillance ProgramAnnals of Pharmacotherapy, 2003
- Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive ActivityJournal of Clinical Microbiology, 2003
- In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and CorynebacteriaAntimicrobial Agents and Chemotherapy, 2003
- Infection with Vancomycin-ResistantStaphylococcus aureusContaining thevanAResistance GeneNew England Journal of Medicine, 2003
- Linezolid resistance in a clinical isolate of Staphylococcus aureusThe Lancet, 2001
- Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolidThe Lancet, 2001
- In VitroEvaluation of BI 397, a Novel Glycopeptide Antimicrobial AgentJournal of Chemotherapy, 2001
- In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibioticJournal of Antimicrobial Chemotherapy, 1999
- Gram-positive resistance: challenge for the development of new antibioticsJournal of Antimicrobial Chemotherapy, 1997
- Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibioticAntimicrobial Agents and Chemotherapy, 1995